Chufeng Zhang

Chufeng Zhang

Auto-generated profile, based on publicly available information

Chufeng Zhang

Department of Oncology Cancer Hospital of Shandong First Medical University Jinan China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
CZChufeng Zhang
Chufeng Zhang
JWJixin Wang
Jixin Wang
ZSZhongwen Sun
Zhongwen Sun
YCYufeng Cao
Yufeng Cao
ZMZhengshuai Mu
Zhengshuai Mu
XJXuMing Ji
XuMing Ji
Immunotherapy against cancer, through immune checkpoint inhibitors targeting the programmed cell death‐1/programmed cell death‐ligand 1 axis, is particularly successful in tumors by relieving the immune escape. However, interindividual responses to immunotherapy are often heterogeneous. Therefore, it is essential to screen out predictive tumor biomarkers. In this study, we analyzed the commensal microbiota in stool samples and paired sputum samples from 75 metastatic non‐small‐cell lung cancer (NSCLC) patients at baseline and during treatment with immune checkpoint inhibitors. Results showed distinct microbes’ signatures between the gut microbiota and paired respiratory microbiota. The alpha diversity between the gut and respiratory microbiota was uncorrelated, and only the gut microbiota alpha diversity was associated with anti‐programmed cell death‐1 response. Higher gut microbiota alpha diversity indicated better response and more prolonged progression‐free survival. Comparison of bacterial communities between responders and nonresponders showed some favorable/unfavorable microbes enriched in responders/nonresponders, indicating that commensal microbiota had potential predictive value for the response to immune checkpoint inhibitors. Generally, some rare low abundance gut microbes and high abundance respiratory microbes lead to discrepancies in microbial composition between responders and nonresponders. A significant positive correlation was observed between the abundance of Streptococcus and CD8+ T cells. These results highlighted the intimate relationship between commensal microbiota and the response to immunotherapy in NSCLC patients. Gut microbiota and respiratory microbiota are promising biomarkers to screen suitable candidates who are likely to benefit from immune checkpoint inhibitor‐based immunotherapy.

31 July 2026 in Cancer Science
Verified
Journal Article
Open access
PDF file
NCNan Cheng
Nan Cheng
RJRuoyu Jiang
Ruoyu Jiang
WLWei Li
Wei Li
WHWenjie Huang
Wenjie Huang
QPQiao Peng
Qiao Peng
CZChufeng Zhang
Chufeng Zhang
Feiwei Heji (FWHJ) is a traditional Chinese medicine formula used for lung cancer with Qi‐Yin deficiency. This study investigated the antitumor effect of FWHJ on lung cancer and explored the underlying mechanisms. The major chemical components of FWHJ were identified by HPLC. Lewis lung carcinoma (LLC) tumor‐bearing mice received oral FWHJ at different doses. Tumor histopathology was assessed by H&E and TUNEL staining. Expression of MLL4, pyroptosis‐related proteins (NLRP3, caspase‐1, and GSDMD), and inflammatory cytokines (IL‐1β and IFN‐β) was detected by Western blot, immunohistochemistry, and ELISA. Tumor‐infiltrating immune cells were evaluated by flow cytometry. An MLL4 overexpression model was established to validate the role of MLL4 in the antitumor effects of FWHJ. HPLC analysis showed that FWHJ primarily contains naringin, chlorogenic acid, amygdalin, and harpagoside. Oral FWHJ significantly inhibited tumor growth, upregulated NLRP3, caspase‐1, and GSDMD, as well as their cleaved forms, and increased the release of IL‐1β and IFN‐β, indicating the activation of pyroptosis. FWJH also enhanced antitumor immunity, characterized by an increased CD8 + /CD4 + T cells ratio and elevated proportion of CD28 + and IFN‐γ + CD8 + T cells in the tumor microenvironment. Mechanistically, FWHJ significantly downregulated MLL4 expression, and MLL4 overexpression largely attenuated its antitumor and immune‐enhancing effects. These findings suggest that FWHJ suppresses lung cancer progression by downregulating MLL4, activating pyroptosis, and promoting immune cell infiltration, highlighting that MLL4 may serve as a key regulator mediating the antitumor effects of FWHJ.